|
EMA Offers Guidance on Marketing Applications for Transdermal Patches
Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives